Immunome, Inc.
IMNM
$27.20
$0.782.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | 69.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | 69.84% |
| Cost of Revenue | 48.04% | 25.79% | 6.01% | 32.24% | 39.09% |
| Gross Profit | -64.36% | -36.63% | -12.44% | -43.46% | -36.37% |
| SG&A Expenses | 81.74% | 21.14% | 15.75% | 14.90% | 43.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.74% | 24.74% | 7.76% | 28.70% | 40.02% |
| Operating Income | -68.11% | -32.92% | -13.06% | -37.25% | -37.93% |
| Income Before Tax | -68.51% | -29.30% | 12.90% | -21.99% | -20.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.51% | -29.30% | 12.90% | -21.99% | -20.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.51% | -29.30% | 12.90% | -21.99% | -20.14% |
| EBIT | -68.11% | -32.92% | -13.06% | -37.25% | -37.93% |
| EBITDA | -68.36% | -33.40% | -12.85% | -37.19% | -38.29% |
| EPS Basic | -29.43% | 9.25% | 42.35% | 16.50% | 17.24% |
| Normalized Basic EPS | -29.45% | 9.25% | 25.00% | 2.62% | -0.29% |
| EPS Diluted | -29.43% | 9.25% | 42.51% | 16.50% | 17.24% |
| Normalized Diluted EPS | -29.45% | 9.25% | 25.00% | 2.62% | -0.29% |
| Average Basic Shares Outstanding | 30.18% | 42.47% | 51.07% | 46.10% | 45.17% |
| Average Diluted Shares Outstanding | 30.18% | 42.47% | 51.07% | 46.10% | 45.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |